BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu PJ. Inflammatory Bowel Disease in Asia: The Challenges and Opportunities. Intest Res. 2015;13:188-190. [PMID: 26130991 DOI: 10.5217/ir.2015.13.3.188] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Lui RNS, Ng SC. The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West? Inflamm Intest Dis 2016;1:78-84. [PMID: 29922661 DOI: 10.1159/000446625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Kang M, Martin A. Microbiome and colorectal cancer: Unraveling host-microbiota interactions in colitis-associated colorectal cancer development. Semin Immunol 2017;32:3-13. [PMID: 28465070 DOI: 10.1016/j.smim.2017.04.003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 12.6] [Reference Citation Analysis]
3 Kwon JH, Im JP, Ye BD, Cheon JH, Jang HJ, Lee KM, Kim YS, Kim SW, Kim YH, Song GA, Han DS, Kim WH, Kim JS. Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study. Gut Liver 2016;10:595-603. [PMID: 27021506 DOI: 10.5009/gnl15411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
4 Hwang SW, Kwak MS, Kim WS, Lee JM, Park SH, Lee HS, Yang DH, Kim KJ, Ye BD, Byeon JS. Influence of a positive family history on the clinical course of inflammatory bowel disease. J Crohns Colitis. 2016;10:1024-1032. [PMID: 26933029 DOI: 10.1093/ecco-jcc/jjw063] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
5 Lee HJ, Song HJ, Jeong JH, Kim HU, Boo SJ, Na SY. Ophthalmologic manifestations in patients with inflammatory bowel disease. Intest Res 2017;15:380-7. [PMID: 28670235 DOI: 10.5217/ir.2017.15.3.380] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
6 Banerjee R, Pal P, Mak JWY, Ng SC. Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1076-88. [PMID: 33181087 DOI: 10.1016/S2468-1253(20)30299-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
7 Park DI. Current status of biosimilars in the treatment of inflammatory bowel diseases. Intest Res. 2016;14:15-20. [PMID: 26884730 DOI: 10.5217/ir.2016.14.1.15] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
8 Kim OZ, Han DS, Park CH, Eun CS, Kim YS, Kim YH, Cheon JH, Ye BD, Kim JS. The Clinical Characteristics and Prognosis of Crohn's Disease in Korean Patients Showing Proximal Small Bowel Involvement: Results from the CONNECT Study. Gut Liver. 2018;12:67-72. [PMID: 28798284 DOI: 10.5009/gnl16500] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Nakata T, Hirano S, Yokota Y, Takahashi H, Kimura B, Kuda T, Eto T, Kato M. Protective effects of heat-killed Lactococcus lactis subsp. lactis BF3, isolated from the intestine of chum salmon, in a murine model of DSS-induced inflammatory bowel disease. Biosci Microbiota Food Health 2016;35:137-40. [PMID: 27508115 DOI: 10.12938/bmfh.2016-007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kim YS, Jung SA, Lee KM, Park SJ, Kim TO, Choi CH, Kim HG, Moon W, Moon CM, Song HK, Na SY, Yang SK; Korean Association for the Study of Intestinal Diseases (KASID). Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2017;15:338-344. [PMID: 28670230 DOI: 10.5217/ir.2017.15.3.338] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
11 Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018;16:233-245. [PMID: 29743836 DOI: 10.5217/ir.2018.16.2.233] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
12 Chan SN, Low END, Raja Ali RA, Mokhtar NM. Delineating inflammatory bowel disease through transcriptomic studies: current review of progress and evidence. Intest Res 2018;16:374-83. [PMID: 30090036 DOI: 10.5217/ir.2018.16.3.374] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
13 Ghoshal UC, Gwee K, Holtmann G, Li Y, Park SJ, Simadibrata M, Sugano K, Wu K, Quigley EMM, Cohen H. The role of the microbiome and the use of probiotics in gastrointestinal disorders in adults in the Asia-Pacific region - background and recommendations of a regional consensus meeting: Gut microbiome/probiotics in Asia-Pacific. Journal of Gastroenterology and Hepatology 2018;33:57-69. [DOI: 10.1111/jgh.13840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
14 Rajbhandari R, Blakemore S, Gupta N, Adler AJ, Noble CA, Mannan S, Nikolli K, Yih A, Joshi S, Bukhman G. Crohn’s disease in low and lower-middle income countries: A scoping review. World J Gastroenterol 2020; 26(43): 6891-6908 [PMID: 33268969 DOI: 10.3748/wjg.v26.i43.6891] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Oh K, Oh EH, Baek S, Song EM, Kim GU, Seo M, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease. PLoS One. 2017;12:e0179266. [PMID: 28622356 DOI: 10.1371/journal.pone.0179266] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
16 Hibi T, Imai Y, Murata Y, Matsushima N, Zheng R, Gasink C. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies. Intest Res 2017;15:475-86. [PMID: 29142515 DOI: 10.5217/ir.2017.15.4.475] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
17 Lee HS, Choe J, Kim SO, Lee SH, Lee HJ, Seo H, Kim GU, Seo M, Song EM, Hwang SW. Overall and cause-specific mortality in Korean patients with inflammatory bowel disease: A hospital-based cohort study. J Gastroenterol Hepatol. 2017;32:782-788. [PMID: 27637573 DOI: 10.1111/jgh.13596] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]